Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons
A9 dopaminergic neurons play a critical role in movement regulation and are disproportionately affected in Parkinson's disease. Historically, researchers have lacked access to viable human models, relying instead on animal studies with limited relevance. With TrailBio ® A9 Dopaminergic Neurons, scientists now have a human-specific platform to investigate disease mechanisms, develop therapies and accelerate drug discovery.
"TrailBio ® A9 Dopaminergic Neurons open new possibilities for Parkinson's research," said Dr. Jan Jensen, Chief Scientific Officer, Chief Technology Officer and founder of Trailhead Biosystems. "These cells enable researchers to study the vulnerabilities of A9 neurons, helping drive progress toward more effective treatments."
"For decades, the lack of human A9 neurons has limited our ability to truly understand Parkinson's disease," added Dr. Nooshin Amini, Scientific Director at Trailhead Biosystems. "Now, with TrailBio ® A9 Dopaminergic Neurons, researchers can directly study the exact cells that are most affected, offering hope for groundbreaking insights and future therapies."
About Trailhead Biosystems
Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE ®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio ® A9 Dopaminergic Neurons represent one of many specialized human cell types emerging from this platform, with additional cell models expected in the near future.
Learn more about Trailhead Biosystems, TrailBio ® A9 Dopaminergic Neurons and HD-DoE ® at www.TrailBio.com.
For more information, please contact:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Canadian Investment Regulatory Organization Trading Halt - CSTL.P Français
VANCOUVER, BC, /CNW/ - The following issues have been halted by CIRO Company: Castlecap Capital Inc. TSX-Venture Symbol: CSTL.P All Issues: Yes Reason: Pending News Halt Time (ET): 10:53 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada. SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions For further information about CIRO's trading halt policy, please see Trading Halts & Timely Disclosure at under the Markets tab. Please note that CIRO staff cannot provide any information about a specific halt beyond what is contained in this halt notice. For general information about CIRO, contact CIRO's Complaints & Inquiries team by submitting a Secure Form located on our contact page at or dialing 1-877-442-4322 (Option 1). For company-related enquiries, please contact the company directly.
Winnipeg Free Press
an hour ago
- Winnipeg Free Press
What to know about Parkinson's disease after Ozzy Osbourne's death
Heavy metal rocker Ozzy Osbourne died this week at 76, just weeks after his farewell show and about five years after announcing he had Parkinson's disease. Here's what to know about the disease: What is Parkinson's? Parkinson's is a neurologic disease that robs people of control over their movements. It typically starts with tremors and is characterized by slow movement, a shuffling gait, stiff limbs, balance problems and slurred speech. Who gets it? About 1 million Americans are living with Parkinson's, and 10 million people worldwide, the Parkinson's Foundation. estimates. It usually appears after age 60, although sometimes it can develop before age 50. What causes Parkinson's? The exact cause isn't known, but Parkinson's develops when cells that produce one of the brain's chemical messengers, called dopamine, begin to deteriorate and die. Dopamine transports signals to parts of the brain that control movement. Parkinson's symptoms appear after enough dopamine-producing cells die that there's too little of this neurotransmitter in the brain. According to the foundation, most experts believe genetic and environmental factors are behind the disease. Dozens of gene mutations linked to Parkinson's have been discovered and genetics account for 10% to 15% of all cases. Other factors suspected of increasing the risk include head injuries, exposure to pesticides and herbicides and where you live. Is there a cure? There is no cure but there are treatments, including medications that affect dopamine levels and a surgically implanted tremor-blocking device. Patients also can benefit from physical and occupational therapy. Wednesdays Columnist Jen Zoratti looks at what's next in arts, life and pop culture. What's the prognosis? Symptoms worsen over time, usually slowly. The severity of symptoms and how quickly they progress varies widely between patients. In advanced cases, people may be unable to walk or care for themselves. They also can suffer from depression as well as memory and thinking problems. While Parkinson's itself isn't considered fatal, people can die from complications of the disease, including lung problems as muscle weakness impedes the ability to cough and to swallow. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Cision Canada
2 hours ago
- Cision Canada
Advisory: CAE's FY2026 Q1 financial results conference call and Annual and Special Meeting of Shareholders 2025 Français
MONTREAL, July 23, 2025 /CNW/ - (NYSE: CAE) (TSX: CAE) – Analysts and institutional investors are invited to virtually attend CAE's FY2026 Q1 financial results conference call on Wednesday, August 13, at 8:00 a.m. Eastern Time (ET). CAE will also hold its FY2025 Annual Meeting of Shareholders at 11:00 a.m. ET on the same day in person and via a live webcast. Please see below for more details. FY2026 first quarter financial results Who: Calin Rovinescu, Chair of the board, Corporate Director Marc Parent, President and Chief Executive Officer Matthew Bromberg, Incoming President and Chief Executive Officer Nick Leontidis, Chief Operating Officer Constantino Malatesta, Interim Chief Financial Officer Andrew Arnovitz, Senior Vice President, Investor Relations and Enterprise Risk Management What: CAE's FY2026 Q1 financial results When: Wednesday, August 13, 2025 – 8:00 a.m. ET Webcast: The conference call will be available via a live audio webcast and a recording will be available following the event at The conference call will also be available via telephone in North America by dialing 1-800-206-4400. International Toll-Free Access to the conference call is available this link. International participants who wish to join the call should click on the link, select the flag of the country where their phone number is registered, complete the form and press the button to submit. They will immediately receive a call on the number provided and will be joined to the conference on a muted line. Afterwards, press *1 to join the question queue. CAE's Annual and Special Meeting of Shareholders 2025 Who: Calin Rovinescu, Chair of the board, Corporate Director Marc Parent, President and Chief Executive Officer Matthew Bromberg, Incoming President and Chief Executive Officer When: Wednesday, August 13, 2025 at 11:00 a.m. ET Where: The Annual and Special Meeting of Shareholders will be held in person at 1250 René-Lévesque Blvd W suite 3610 36th floor, Montreal, Quebec H3B 4W8 and via a live webcast. A recording will be available following the event at About CAE At CAE, we exist to make the world safer. We deliver cutting-edge training, simulation, and critical operations solutions to prepare aviation professionals and defence forces for the moments that matter. Every day, we empower pilots, cabin crew, maintenance technicians, airlines, business aviation operators, and defence and security personnel to perform at their best and when the stakes are the highest. Around the globe, we're everywhere customers need us to be, with approximately 13,000 employees at around 240 sites and training locations in over 40 countries. For nearly 80 years, CAE has been at the forefront of innovation, consistently seeking to set the standard by delivering excellence in high-fidelity flight simulators and training solutions, while embedding sustainability at the heart of everything we do. By harnessing technology and enhancing human performance, we strive to be the trusted partner in advancing safety and mission readiness - today and tomorrow. Read our FY25 Global Annual Activity and Sustainability Report. CAE Contacts:
